Publication in early January of the genetic make-up to SARS-CoV-2 catalyzed research efforts across the globe, in academic as well as biotech and pharmaceutical company laboratories.
Nearly 20 groups are now developing coronavirus vaccines, including Johnson & Johnson and, more recently, Sanofi. Another nine organizations are conducting initial tests on therapeutics, according to a Feb. 7 count by BioCentury.
Solving the virus’ DNA also revealed the likely method by which SARS-CoV-2 enters human cells, giving researchers a potential target for their development work.
